AVDL - Avadel Pharmaceuticals plc
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Dublin,
Ireland
Type: Equity
AVDL price evolution
AVDL
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $28.85 | $35.79 | $31.17 | |
| Short term investments | $42.53 | $52.99 | $73.94 | |
| Net receivables | $37.1 | $34.3 | $22.69 | $12.1 |
| Inventory | $16.1 | $13.31 | $11.93 | $10.38 |
| Total current assets | $127.26 | $125.78 | $136.03 | $134.2 |
| Long term investments | ||||
| Property, plant & equipment | $2.4 | $2.64 | $2.9 | $3.18 |
| Goodwill & intangible assets | $16.84 | $16.84 | $16.84 | |
| Total noncurrent assets | $31.74 | $31.86 | $30.5 | |
| Total investments | $42.53 | $52.99 | $73.94 | |
| Total assets | $158.25 | $157.52 | $167.9 | $164.7 |
| Current liabilities | ||||
| Accounts payable | $7.92 | $9.79 | $18.96 | $11.43 |
| Deferred revenue | ||||
| Short long term debt | $0.87 | $0.95 | $0.93 | |
| Total current liabilities | $42.78 | $44.61 | $47.81 | $36.85 |
| Long term debt | $36.8 | $35.78 | $34.45 | |
| Total noncurrent liabilities | $42.62 | $41.71 | $40.1 | |
| Total debt | $37.67 | $36.73 | $35.38 | |
| Total liabilities | $83.59 | $87.23 | $89.52 | $76.96 |
| Shareholders' equity | ||||
| Retained earnings | -$789.28 | -$786.66 | -$772.84 | -$745.5 |
| Other shareholder equity | -$24 | -$24.43 | -$23.76 | -$23.17 |
| Total shareholder equity | $70.29 | $78.38 | $87.74 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $31.17 | $73.98 | $50.71 | $71.72 |
| Short term investments | $73.94 | $22.52 | $106.51 | $149.68 |
| Net receivables | $12.1 | $2.59 | $31.82 | $39.1 |
| Inventory | $10.38 | |||
| Total current assets | $134.2 | $100.84 | $192.49 | $263.45 |
| Long term investments | ||||
| Property, plant & equipment | $3.18 | $2.55 | $2.94 | $2.96 |
| Goodwill & intangible assets | $16.84 | $16.84 | $16.84 | $16.84 |
| Total noncurrent assets | $30.5 | $31.94 | $54.77 | $48.18 |
| Total investments | $73.94 | $22.52 | $106.51 | $149.68 |
| Total assets | $164.7 | $132.78 | $247.26 | $311.64 |
| Current liabilities | ||||
| Accounts payable | $11.43 | $7.89 | $7.68 | $2.93 |
| Deferred revenue | ||||
| Short long term debt | $0.93 | $38.63 | $0.9 | $0.47 |
| Total current liabilities | $36.85 | $55.79 | $21 | $15.11 |
| Long term debt | $34.45 | $91.61 | $144.1 | $130.05 |
| Total noncurrent liabilities | $40.1 | $98.14 | $148.02 | $134.26 |
| Total debt | $35.38 | $131.02 | $145 | $130.52 |
| Total liabilities | $76.96 | $153.93 | $169.02 | $149.37 |
| Shareholders' equity | ||||
| Retained earnings | -$745.5 | -$585.22 | -$447.76 | -$384.19 |
| Other shareholder equity | -$23.17 | -$24.45 | -$23.94 | -$21.05 |
| Total shareholder equity | $87.74 | -$21.14 | $78.24 | $162.27 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $50.02 | $41.5 | $27.18 | $19.45 |
| Cost of revenue | $2.79 | $1.52 | $0.69 | |
| Gross Profit | $43.87 | $38.72 | $25.66 | $18.76 |
| Operating activities | ||||
| Research & development | $4.05 | $3.07 | $2.36 | |
| Selling, general & administrative | $47.41 | $48.62 | $41.3 | |
| Total operating expenses | $44.2 | $51.46 | $51.69 | $43.66 |
| Operating income | -$12.74 | -$26.04 | -$24.9 | |
| Income from continuing operations | ||||
| EBIT | -$11.62 | -$24.66 | -$26.53 | |
| Income tax expense | $0.09 | -$0.51 | $0.09 | -$0.1 |
| Interest expense | -$2.82 | $2.72 | $2.59 | $2.35 |
| Net income | ||||
| Net income | -$2.63 | -$13.82 | -$27.34 | -$28.79 |
| Income (for common shares) | -$13.82 | -$27.34 | -$28.79 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $27.96 | $22.33 | ||
| Cost of revenue | $0.85 | $5.74 | ||
| Gross Profit | $27.12 | $16.59 | ||
| Operating activities | ||||
| Research & development | $13.26 | $20.7 | $17.1 | $20.44 |
| Selling, general & administrative | $151.71 | $74.52 | $68.5 | $32.41 |
| Total operating expenses | $164.97 | $98.56 | $85.55 | $7.45 |
| Operating income | -$137.85 | -$98.56 | -$85.55 | $9.14 |
| Income from continuing operations | ||||
| EBIT | -$150.89 | -$99.1 | -$83.2 | $7.91 |
| Income tax expense | -$0.5 | $26.02 | -$15.82 | -$12.11 |
| Interest expense | $9.89 | $12.34 | $9.94 | $12.99 |
| Net income | ||||
| Net income | -$160.28 | -$137.46 | -$77.33 | $7.03 |
| Income (for common shares) | -$160.28 | -$137.46 | -$77.33 | $7.03 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$13.82 | -$27.34 | -$28.79 | |
| Operating activities | ||||
| Depreciation | $0.44 | $0.54 | -$0.02 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.46 | $5.39 | $3.52 | |
| Total cash flows from operations | -$18.19 | -$29.7 | -$28.03 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $10.55 | $21.39 | $27.93 | |
| Total cash flows from investing | $36.87 | $10.55 | $21.39 | $27.93 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.72 | $13.19 | $0.05 | |
| Net borrowings | -$21.16 | |||
| Total cash flows from financing | $15.09 | $0.72 | $13.19 | -$21.11 |
| Effect of exchange rate | $0.24 | -$0.03 | -$0.25 | $0.57 |
| Change in cash and equivalents | -$2.59 | -$6.95 | $4.63 | -$20.64 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$160.28 | -$137.46 | -$77.33 | $7.03 |
| Operating activities | ||||
| Depreciation | $1.77 | $1.49 | $0.81 | $1.69 |
| Business acquisitions & disposals | $16.5 | $25.5 | ||
| Stock-based compensation | $15.81 | $7.01 | $8.87 | $3 |
| Total cash flows from operations | -$128.51 | -$70.3 | -$77.31 | -$48.73 |
| Investing activities | ||||
| Capital expenditures | -$0.72 | -$0.03 | -$0.1 | |
| Investments | -$50.09 | $80.41 | $40.45 | -$95.12 |
| Total cash flows from investing | -$50.09 | $79.7 | $56.93 | -$69.72 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $148.36 | $28 | $0.26 | $179.68 |
| Net borrowings | -$13.02 | -$13.46 | ||
| Total cash flows from financing | $135.34 | $14.54 | $0.26 | $179.68 |
| Effect of exchange rate | $0.46 | -$0.66 | -$0.9 | $0.72 |
| Change in cash and equivalents | -$42.81 | $23.27 | -$21.01 | $61.95 |
News
Fundamentals
| Market cap | $762.05M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 90.61M |
| Revenue | $138.16M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$72.58M |
| Revenue Q/Q | 613.22% |
| Revenue Y/Y | 1.52K% |
| P/E ratio | -10.50 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 5.52 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.80 |
|---|---|
| ROA | -44.77% |
| ROE | N/A |
| Debt/Equity | 0.88 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.97 |
| Quick ratio | 2.60 |